Haemocomplettan® P + Human albumin (Placebo)
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fibrinogen Deficiency in Complex Cardiac Surgery
Conditions
Fibrinogen Deficiency in Complex Cardiac Surgery
Trial Timeline
Feb 1, 2011 → Dec 1, 2014
NCT ID
NCT01124981About Haemocomplettan® P + Human albumin (Placebo)
Haemocomplettan® P + Human albumin (Placebo) is a phase 2/3 stage product being developed by CSL for Fibrinogen Deficiency in Complex Cardiac Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT01124981. Target conditions include Fibrinogen Deficiency in Complex Cardiac Surgery.
What happened to similar drugs?
1 of 5 similar drugs in Fibrinogen Deficiency in Complex Cardiac Surgery were approved
Approved (1) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01124981 | Phase 2/3 | Completed |
Competing Products
9 competing products in Fibrinogen Deficiency in Complex Cardiac Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fibrinogen Concentrate, Human (FCH) + Cryoprecipitate | CSL | Phase 3 | 32 |
| FCH | CSL | Pre-clinical | 26 |
| CSL511 Fibrinogen concentrate (human) + Cryoprecipitate | CSL | Phase 3 | 47 |
| Human Fibrinogen Concentrate | CSL | Phase 2 | 35 |
| BT524 (Part I) + BT524 (Part II) | ICON plc. | Phase 3 | 37 |
| FIB Grifols | Grifols | Phase 3 | 29 |
| Human Plasma-Derived Fibrinogen Concentrate | Grifols | Phase 1/2 | 29 |
| Pathogen Reduced Cryoprecipitated Fibrinogen Complex + Cryoprecipitated-Antihemophilic Factor | Cerus | Pre-clinical | 23 |
| Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate | Cerus | Approved | 33 |